Barely a week after cutting a deal with Beigene Ltd. that included an up-front of $45 million cash, Shoreline Biosciences Inc. and Gilead Sciences Inc.-owned Kite are collaborating to develop allogeneic cell therapies in a deal that could bring Shoreline more than $2.3 billion plus royalties.

LONDON – The alchemy of induced pluripotent cells has broken another barrier, delivering a model of the earliest preimplantation stages of human development, when fertilized eggs form a blastocyst.

DUBLIN – Cellectis SA is picking up $15 million worth of equity in Cytovia Therapeutics Inc. and could earn as much as $760 million in development, regulatory and sales milestones from a deal involving up to five gene-edited allogeneic natural killer (NK) cell or chimeric antigen receptor (CAR-NK) cell therapies employing its Talen (transcription activator-like effector nuclease) gene editing technology.

PERTH, Australia – Melbourne-based regenerative medicine company Cynata Therapeutics Ltd. is gearing up to take its Cymerus mesenchymal stem cell (MSC) product candidate, CYP-004, into a phase III trial in osteoarthritis.

Aspen Neuroscience Inc. hopes to get into the clinic to test autologous neuron replacement in Parkinson’s disease with a $6.5 million seed round. The financing featured several established life sciences venture investors; it was led by Domain Associates and Axon Ventures and included Alexandria Venture Investments, Arch Venture Partners, Orbimed, and Section 32.